CN108992663A - It is a kind of for preventing and treating the compound preparation of pet's oral cavity class disease - Google Patents
It is a kind of for preventing and treating the compound preparation of pet's oral cavity class disease Download PDFInfo
- Publication number
- CN108992663A CN108992663A CN201811026174.XA CN201811026174A CN108992663A CN 108992663 A CN108992663 A CN 108992663A CN 201811026174 A CN201811026174 A CN 201811026174A CN 108992663 A CN108992663 A CN 108992663A
- Authority
- CN
- China
- Prior art keywords
- parts
- compound preparation
- pet
- oral cavity
- class disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
Abstract
The present invention provides a kind of for preventing and treating the compound preparation of pet's oral cavity class disease, the compound preparation, including following raw material: lysozyme, glycine, aspartic acid, nitric acid VB1, VB2, menthol, montmorillonite, the compound preparation, in parts by weight, including following raw material components: lysozyme: 0.03-0.15 parts；Glycine: 0.30-1.5 parts；Aspartic acid: 0.12-0.28 parts；VB1:0.012-0.028 parts of nitric acid；VB2:0.03-0.07 parts, menthol: 0.12 part；Montmorillonite adds to 12 parts.Compound preparation of the present invention is widely used in damage, inflammation or the ulcer of the cat of each age group, dog oral mucosa, gum and lip, lip bubble rash, artificial tooth backing pressure sore etc., and can stick affected part, plays analgesic and promotes affected part healing；Dressing after can also making tooth extraction and dental calculus curettage.It can also be used in angular stomatitis, thick libngual fur and white, oral peculiar smell.
Description
Technical field
The present invention relates to the veterinary drug technical fields of pet bio-pharmaceuticals, more particularly to prevention and treatment pet dog, the oral cavity class of cat
The composition of the compound preparation of disease forms.
Background technique
Currently, China's economic is in pet industry fast-developing period, Yang Chong family is increasing, by 2017 this
A number has reached 59,120,000, and still increase by a fairly big margin space.Chinese pet dog cat quantity reaches 87,460,000, dotes on user supporting
In, Yang Gou family ratio highest 49,900,000 reaches 60%；It keeps a cat 37,560,000, ratio is main pets close to 40%
Not.Pet industry size reaches 134,000,000,000 yuan within 2017, it is contemplated that in the year two thousand twenty then nearly 200,000,000,000.And pet drug 2016 sell
For volume up to 14,700,000,000 yuan, accounting for industry size is 12%；The product for wherein treating oral cavity class is more rare, and class drug category is single is for treatment
The current status of pet drug.
Pet serves as the role of child or relatives in family.Currently, pet's oral cavity class disease increases, and has become to support and dote on
A kind of puzzlement of family.As often there is the damage of oral mucosa inflammation or ulcer, gum and lip, lip bubble rash, angular stomatitis, portion
Divide and extraction and dental calculus is needed to strike off.Pet industry is substantially from brushing teeth and toothpaste, film, the food that cleans the teeth angularly are started with solution
Problem, seldom from pharmaceutical point, itself is exactly problem such as the problem of ulcer, is all difficult to solve on the person, mostly voluntarily with the time
Recovery from illness.And difficulty has similar products on pet market, regular person is very fewer, therefore provides for pet dog, cat a kind of efficiently anti-
It controls pet's oral cavity class disease and the preparation of administration is facilitated to have become a very promising research direction.
The preparation of existing prevention and treatment pet's oral cavity class disease, haves the defects that treatment cycle is long, cure rate is low.
Summary of the invention
To solve the shortcomings of the prior art, the present invention provides a kind of for preventing and treating the compound system of pet's oral cavity class disease
Agent, to realize following goal of the invention:
(1) treatment cycle is short, cure rate is high.
(2) convenient drug administration (drug is sprayed at affected part), dosage are accurate, curative effect collaboration, reach analgesic and promote to suffer from
Affected part and tool protective effect are sticked in place's healing.
To solve the above-mentioned problems, the invention adopts the following technical scheme:
It is a kind of for preventing and treating the compound preparation of pet's oral cavity class disease, said preparation is prepared from the following raw materials in parts by weight: bacteriolyze
Enzyme: 0.03-0.15 parts；Glycine: 0.30-1.5 parts；Aspartic acid: 0.12-0.28 parts；VB1:0.012-0.028 parts of nitric acid；
VB2:0.03-0.07 parts；Menthol: 0.12 part；Montmorillonite adds to 12 parts；Total total amount: 12 parts.
It is that the present invention advanced optimizes above scheme below:
Said preparation is prepared from the following raw materials in parts by weight: lysozyme: 0.12 part；Glycine: 1.2 parts；Aspartic acid: 0.24
Part；VB1:0.024 parts of nitric acid；VB2:0.06 parts；Menthol: 0.12 part；Montmorillonite: 10.236 parts；Total total amount: 12 parts.
Another kind optimization:
Said preparation is prepared from the following raw materials in parts by weight: lysozyme: 0.03 part；Glycine: 0.30 part；Aspartic acid: 0.12
Part；VB1:0.012 parts of nitric acid；VB2:0.03 parts；Menthol: 0.12 part；Montmorillonite: 11.388 parts；Total total amount: 12 parts.
Another kind optimization:
Said preparation is prepared from the following raw materials in parts by weight: lysozyme: 0.06 part；Glycine: 0.60 part；Aspartic acid: 0.16
Part；VB1:0.016 parts of nitric acid；VB2:0.04 parts；Menthol: 0.12 part；Montmorillonite: 11.004 parts；Total total amount: 12 parts.
Another kind optimization:
Said preparation is prepared from the following raw materials in parts by weight: lysozyme: 0.09 part；Glycine: 0.90 part；Aspartic acid: 0.20
Part；VB1:0.020 parts of nitric acid；VB2:0.05 parts；Menthol: 0.12 part；Montmorillonite: 10.62 parts；Total total amount: 12 parts.
Another kind optimization:
Said preparation is prepared from the following raw materials in parts by weight: lysozyme: 0.15 part；Glycine: 1.5 parts；Aspartic acid: 0.28
Part；VB1:0.028 parts of nitric acid；VB2:0.07 parts；Menthol: 0.12 part；Montmorillonite: 9.852 parts；Total total amount: 12 parts.
The present invention also provides a kind of for preventing and treating the preparation process of the compound preparation of pet's oral cavity class disease, including following step
It is rapid:
1, aspartic acid, glycine, menthol co-grinding are crossed into 80 meshes；
2, lysozyme, nitric acid VB1, VB2 are added in 1 and carry out level-one mixing；
3, it takes equivalent montmorillonite to carry out second level with primary mixes to mix；
4, two-stage mixture and remaining montmorillonite are finally mixed.After detection is qualified, packing.
Beneficial effects of the present invention:
(1) compound preparation of the present invention be widely used in the cat of each age group, dog oral mucosa, gum and lip damage,
Inflammation or ulcer, lip bubble rash, artificial tooth backing pressure sore etc., and affected part can be sticked, play analgesic and promote affected part healing；It can also make tooth extraction
And the dressing after dental calculus curettage.It can also be used in angular stomatitis, thick libngual fur and white, oral peculiar smell.It is administered simple and convenient, drug is sprayed
It is applied to affected part.
(2) product of the present invention is used for the oral cavity class disease of pet, and first course for the treatment of (7 days) cure rate is 70.0-71.8%；Make
With existing product, the cure rate after 7 days is 41-43.75%, and using product of the present invention than existing product, cure rate is high about after 7 days
30 percentage points；
It the use of second course for the treatment of of product of the present invention (14 days) cure rate is 97.5-98.6%；Healing using existing product, after 14 days
Rate is 88-89.5%, and using product of the present invention than existing product, cure rate is about 8-12 percentage points high after 14 days.
Below by specific embodiment, the invention will be further described, but the present invention is not limited by following embodiment
It is fixed.
Specific embodiment
It is a kind of for preventing and treating the compound preparation of pet's oral cavity class disease, said preparation is prepared from the following raw materials in parts by weight:
The raw material proportioning of the compound preparation of 1 embodiment 1-5 of table
Embodiment 4 is preferred embodiment.
The compound preparation of the present invention of embodiment 6 is used to prevent and treat the test of pet's oral cavity class disease
The present invention carries out following tests using product described in embodiment 4:
Pet test site: pet dog breeding farm Weifang A(), pet dog breeding farm Weifang B() and the Weifang pet clinic C(), dote on
The Qingdao object hospital D(), add up to four part test places.
Operational staff: 4 practising veterinarians are worked at a selected spot and are tested, and record test data.
Test is related to case 624, wherein farm's kind of dog 8, outpatient service kind of dog 15, across the gestational period, childhood, not at
Year, adult, aged 5 stages；Take random experiment, and set up blank control or product control, according to weight calculate dosage into
Row is oral, observes and records result.
Practising veterinarian carries out routine examination and records before testing, and Pass Test dog requires just can be to be diagnosed as oral cavity class disease
The case of disease could participate in testing, and carry out record and data statistic analysis.
Medication: 1, disease phase and convalescence: being sprayed at affected part for drug, once a day, 1/5 bottle every time；Serious disease
Example (having seriously affected feeding and drinking-water) is secondary daily, is used continuously 5-7 days, every time 1/5 bottle；Specification: 10g/ bottles.
(1) small sample test data: pet dog breeding farm Weifang A(), pet dog breeding farm Weifang B() respectively select 12 (examination
Test+compare), the above test dog sample standard deviation is diagnosed as ulcer or stomatitis in the class disease of oral cavity, that is, meets this test requirements document, respectively
Age bracket does not differentiate between, and data are mixing statistics；It is 24 (test+control) total.The above test dog sample standard deviation is diagnosed as single mouth
Chamber class disease symptoms.
The sample distribution of test group and control group, is consistent before the treatment.
The compound preparation of the present invention of table 2 is used for the therapeutic effect of breeding farm pet dog oral cavity class disease
Note: pet dog breeding farm A, B two respectively sets 1 group of test group and 1 group of control group, and test group is to use the embodiment of the present invention 4
Product, control group is blank control.
As a result: since ulcer, stomatitis class disease majority are chronic diseases, after especially deteriorating, it is impossible to rehabilitation in a short time, application
After product of the present invention, the rate of fully recovering is above 50% after first course for the treatment of, reaches 50-60%；The rate of fully recovering reaches after two courses for the treatment of
100%.Control group aggravates after first course for the treatment of, has 3 corruptions occur in two control group 4 after second course for the treatment of, 1 goes out
It now improves, and in voluntarily rehabilitation in the 24th day.Analysis the reason is that, case is selected from single oral cavity class disease, without pernicious infectiousness and
Organ deficiency damages class disease, and body founction metabolism is vigorous, shoulders gradually voluntarily rehabilitation after the clinical symptoms obvious phase, but the time is unrestrained
It is long.It can be seen that product of the present invention can accelerate the healing of oral cavity class disease, significantly shortening treatment cycle.
(2) similar product comparative test:
Puppy, adult dogs, aged dog blended data: since test sample quantity is big, and disperse, so being divided at random using blind
Group.
The comparison of table 3 product of the present invention and existing similar product
Note: test group and control group respectively set 2 groups, and test group sets 3,4 groups as using the product of the embodiment of the present invention 4, control group 3,4
Using Liang Jia test unit (pet clinic C D) at present with product.
As a result: for according to the random medication of weight in test；From the point of view of test result analysis, two groups to impinging upon second treatment
After journey, cure rate is respectively 88.75% and 89.5%, this illustrates that pet clinic is also very prudent when selecting product.
Test group is more excellent, and 2 course cure rates are respectively 97.5% and 98.6%, is higher by 9 percentage points of control group or so.
In terms of the therapeutic effect that first course for the treatment of terminates, then product of the present invention therapeutic effect significant difference.Test group is cured
Rate is respectively cure rate 70.0% and 71.8%；It is higher by about 30 percentage points of two control group cure rates 43.75% and 41.8%；Thus
It can be seen that the present invention can be such that treatment cycle is obviously shortened.
Above-described embodiment is all to be conceived using this and actually made for illustrating inventive concept and actual use of the invention
With making a non-material change to the present invention, protection scope of the present invention should all be fallen into.
Claims (7)
1. a kind of for preventing and treating the compound preparation of pet's oral cavity class disease, it is characterised in that: the compound preparation, including following original
Material: lysozyme, glycine, aspartic acid, nitric acid VB1, VB2, menthol, montmorillonite.
2. according to claim 1 a kind of for preventing and treating the compound preparation of pet's oral cavity class disease, it is characterised in that: described
Compound preparation, in parts by weight, including following raw material components: lysozyme: 0.03-0.15 parts；Glycine: 0.30-1.5 parts；It
Aspartic acid: 0.12-0.28 parts；VB1:0.012-0.028 parts of nitric acid；VB2:0.03-0.07 parts；Menthol: 0.12 part；Montmorillonite
Add to 12 parts.
3. according to claim 1 a kind of for preventing and treating the compound preparation of pet's oral cavity class disease, it is characterised in that: described
Compound preparation, in parts by weight, including following raw material components: lysozyme: 0.12 part；Glycine: 1.2 parts；Aspartic acid: 0.24
Part；VB1:0.024 parts of nitric acid；VB2:0.06 parts；Menthol: 0.12 part；Montmorillonite: 10.236 parts.
4. according to claim 1 a kind of for preventing and treating the compound preparation of pet's oral cavity class disease, it is characterised in that: described
Compound preparation, in parts by weight, including following raw material components: lysozyme: 0.03 part；Glycine: 0.30 part；Aspartic acid:
0.12 part；VB1:0.012 parts of nitric acid；VB2:0.03 parts；Menthol: 0.12 part；Montmorillonite: 11.388 parts.
5. according to claim 1 a kind of for preventing and treating the compound preparation of pet's oral cavity class disease, it is characterised in that: described
Compound preparation, in parts by weight, including following raw material components: lysozyme: 0.06 part；Glycine: 0.60 part；Aspartic acid:
0.16 part；VB1:0.016 parts of nitric acid；VB2:0.04 parts；Menthol: 0.12 part；Montmorillonite: 11.004 parts.
6. according to claim 1 a kind of for preventing and treating the compound preparation of pet's oral cavity class disease, it is characterised in that: described
Compound preparation, in parts by weight, including following raw material components: lysozyme: 0.09 part；Glycine: 0.90 part；Aspartic acid:
0.20 part；VB1:0.020 parts of nitric acid；VB2:0.05 parts；Menthol: 0.12 part；Montmorillonite: 10.62 parts.
7. according to claim 1 a kind of for preventing and treating the compound preparation of pet's oral cavity class disease, it is characterised in that: described
Compound preparation, in parts by weight, including following raw material components: lysozyme: 0.15 part；Glycine: 1.5 parts；Aspartic acid: 0.28
Part；VB1:0.028 parts of nitric acid；VB2:0.07 parts；Menthol: 0.12 part；Montmorillonite: 9.852 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811026174.XA CN108992663A (en) | 2018-09-04 | 2018-09-04 | It is a kind of for preventing and treating the compound preparation of pet's oral cavity class disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811026174.XA CN108992663A (en) | 2018-09-04 | 2018-09-04 | It is a kind of for preventing and treating the compound preparation of pet's oral cavity class disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108992663A true CN108992663A (en) | 2018-12-14 |
Family
ID=64591528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811026174.XA Withdrawn CN108992663A (en) | 2018-09-04 | 2018-09-04 | It is a kind of for preventing and treating the compound preparation of pet's oral cavity class disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108992663A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111686243A (en) * | 2020-07-16 | 2020-09-22 | 上海中华药业有限公司 | Composition for inhibiting oral pathogenic bacteria and application thereof |
| CN111840126A (en) * | 2020-07-16 | 2020-10-30 | 上海中华药业有限公司 | Oral care agent with antibacterial effect and preparation method thereof |
| CN112121105A (en) * | 2020-09-15 | 2020-12-25 | 长江大学 | Mouthwash spray for pets and preparation method thereof |
| CN113892557A (en) * | 2021-09-14 | 2022-01-07 | 有鱼有品(深圳)生物技术有限公司 | Pet food component with function of improving halitosis |
-
2018
- 2018-09-04 CN CN201811026174.XA patent/CN108992663A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111686243A (en) * | 2020-07-16 | 2020-09-22 | 上海中华药业有限公司 | Composition for inhibiting oral pathogenic bacteria and application thereof |
| CN111840126A (en) * | 2020-07-16 | 2020-10-30 | 上海中华药业有限公司 | Oral care agent with antibacterial effect and preparation method thereof |
| CN112121105A (en) * | 2020-09-15 | 2020-12-25 | 长江大学 | Mouthwash spray for pets and preparation method thereof |
| CN113892557A (en) * | 2021-09-14 | 2022-01-07 | 有鱼有品(深圳)生物技术有限公司 | Pet food component with function of improving halitosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108992663A (en) | It is a kind of for preventing and treating the compound preparation of pet's oral cavity class disease | |
| Hamberg | Controlled trial of fluoride in vitamin drops for prevention of caries in children | |
| Jones et al. | Incidence and indications for surgical management of phenytoin-induced gingival overgrowth in a cerebral palsy population | |
| DAHL et al. | Idiopathic hypoparathyroidism associated with hyperthyroidism | |
| CN110882345B (en) | Traditional Chinese medicine composition for preventing and treating postpartum abdominal pain of dairy cows and preparation method thereof | |
| Lowe et al. | Pilot study of the effectiveness of a xylitol-based drinking water additive to reduce plaque and calculus accumulation in dogs | |
| Li-mei et al. | Comparative observation on the effects of Radix tripterygium hypoglaucum tablet and Tripterygium glycosides tablet in treating erosive oral lichen planus | |
| CN108704077B (en) | Traditional Chinese veterinary medicine composition for treating cat stomatitis and preparation method thereof | |
| CN103055219B (en) | A kind of respiratory diseases in pigs health care Chinese medicine powder and preparation technology thereof | |
| CN1660274A (en) | Combination of lmedication for treatig mastitis of cow and preparation method | |
| Bostanabad et al. | The effect of mucoadhesive gel containing Satureja hortensis extract 1% on severity of chemotherapy-induced mucositis pain in children: a randomized clinical trial | |
| CN103191414B (en) | Fast-absorbed liquid calcium for pet and preparation method thereof | |
| CN109258947A (en) | A kind of compound preparation enriched blood for piglet | |
| DE69729120T2 (en) | DRUG COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF FYBROMYALGIA AND CHRONIC TEMPTATION SYNDROME | |
| CN1164283C (en) | Pulmonotis treating Chinese medicine powder | |
| US8524759B2 (en) | Phenylbutazone carrier formulation showing increased bioactivity in animals | |
| CN113058030B (en) | Composition for preventing and treating flaccidity syndrome and application thereof | |
| Alshukairi et al. | Knowledge of the teething process and assessment of the relieving practices amongst mothers in Riyadh, Saudi Arabia | |
| Downs Jr | Studies in the causes of dental anomalies | |
| Khofifah et al. | The Effectiveness of Ethanolic Extract of Centella asiatica (L.) on Healing Minor Recurrent Aphthous Stomatitis in Wistar Male Rats (Rattus norvegicus) | |
| Abarbanel | Clinical Evaluation of Adjunctive Therapy with Stilbestrol Monomethyl Ether with Comments on Toxicity | |
| CN109157655A (en) | A kind of compound preparation for pet postoperative rehabilitation | |
| Makhlynets | THE USE OF MEDICINES BASED ON HYALURONIC ACID IN THE COMPLEX TREATMENT OF DISORDERS OF THE ARCHTECTONICS OF THE VESTIBULE OF THE MOUTH | |
| CN111249379A (en) | Chinese herbal medicine formula for resisting stress response of cattle in long-distance transportation and preparation method and application thereof | |
| CN106237250A (en) | A kind of Chinese medicine composition treating prostatic hyperplasia and capsule thereof and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181214 |